{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/management/general-principles-of-managing-dmards/","result":{"pageContext":{"chapter":{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs","depth":2,"htmlHeader":"<!-- begin field a0a2167f-448f-40ea-990c-08dcd67d7245 --><h2>Scenario: General principles of managing DMARDs</h2><!-- end field a0a2167f-448f-40ea-990c-08dcd67d7245 -->","summary":"Covers the general principles of managing an adult who is on a DMARD.","htmlStringContent":"<!-- begin item e76f7d11-7add-47e7-800b-a06a569f9b78 --><!-- begin field c1685041-d3f6-4ccd-9db3-acbc015c27a4 --><p>From age 18 years onwards.</p><!-- end field c1685041-d3f6-4ccd-9db3-acbc015c27a4 --><!-- end item e76f7d11-7add-47e7-800b-a06a569f9b78 -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"76602c52-c241-5149-af49-8c34564e273d","slug":"general-principles-of-managing-dmards","fullItemName":"General principles of managing DMARDs","depth":3,"htmlHeader":"<!-- begin field 7788f5e0-e515-416b-a122-24050bf9b472 --><h3>What are the general principles of managing DMARDs?</h3><!-- end field 7788f5e0-e515-416b-a122-24050bf9b472 -->","summary":null,"htmlStringContent":"<!-- begin item d2468490-5baf-4c04-8d75-837e100be70f --><!-- begin field 08b03d2c-9897-4951-a437-601c66408cca --><ul><li><strong>Prescribing disease-modifying anti-rheumatic drugs (DMARDs) is always part of a shared-care protocol. </strong>Treatment and initial monitoring are usually carried out by a specialist in secondary care. Once the person is stabilized on treatment, the GP may be asked to:<ul><li><strong>Prescribe and monitor the DMARD.</strong><ul><li>When prescribing a DMARD always follow the recommendations of local guidelines where they differ from those given in this CKS topic.</li><li>Whilst absolute values are useful indicators when monitoring a person on a DMARD, trends are equally important, and any rapid fall or rise, or a consistent downward or upward trend in any parameter warrants extra vigilance (for example, gradual decreases in white blood cells or albumin, or increasing liver enzymes).</li><li>People who are on one DMARD are likely to be taking a second (for example, methotrexate or sulfasalazine), or even a third. Monitoring of people on more than one DMARD should be based on the DMARD which requires the most frequent monitoring.</li><li>For information on when to refer a person taking a DMARD, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dmards/management/general-principles-of-managing-dmards/#when-to-refer\">when to refer</a>.</li></ul></li><li><strong>Monitor the person's health and liaise with their consultant regarding any complication of therapy.</strong><ul><li>People who are taking DMARDs are more prone to infection, especially in the first 6 months of treatment.</li><li>Advise the person to avoid contact with people that have shingles or chickenpox. If they come in to contact with these people, they must seek urgent medical advice.</li></ul></li><li><strong>Be aware of any adverse effects related to the DMARD.</strong><ul><li>Check the manufacturer's Summary of Product Characteristics for each DMARD, available at the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"460c2e5d-78b8-464d-a5ed-a931009fc0d9\">www.medicines.org.uk</a>).</li></ul></li><li><strong>Be aware that major toxicity with DMARDs can occur during intercurrent illness</strong>, particularly if there is impairment of renal function or sepsis. <ul><li>Seek specialist advice, as treatment may need to be temporarily discontinued.</li></ul></li><li><strong>Avoid prescribing medicines which have the potential to interact with DMARDs.</strong><ul><li>For more detailed information about DMARDs and drug interactions, check the manufacturer's Summary of Product Characteristics, available at the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"bf40bb52-c4f1-42c8-97eb-a931009fc14a\">www.medicines.org.uk</a>).</li></ul></li><li><strong>Offer vaccinations to prevent serious infections that are more common in people exposed to DMARDs.</strong><ul><li>An annual influenza vaccine should be given, and a pneumococcal vaccine should be given preferably before starting the DMARD. Pneumococcal vaccine should be repeated at 10-yearly intervals if given before starting the DMARD, or at 5-yearly intervals if given after starting the DMARD.</li><li>Live vaccines (for example, yellow fever and rubella) are contraindicated for people who are on DMARDs. Always seek specialist advice if a live vaccine is being considered.</li></ul></li><li><strong>Ensure that people on DMARDS have been provided with suitable medicines information leaflets </strong>and are aware of potential adverse effects, as well as who to contact if these should develop. Patient information leaflets are available from the following websites:<ul><li><a href=\"http://www.arthritiscare.org.uk/Home\" data-hyperlink-id=\"71e773bb-5f2a-47eb-96b6-a931009fc1c5\">Arthritis Care</a>.</li><li><a href=\"http://www.arthritisresearchuk.org/\" data-hyperlink-id=\"017d311e-3867-42e3-a84c-a931009fc24d\">Arthritis Research UK</a>.</li><li><a href=\"http://www.rheumatoid.org.uk/\" data-hyperlink-id=\"14b32eaa-d8bf-4953-ae31-a931009fc2ae\">National Rheumatoid Arthritis Society</a>.</li></ul></li></ul></li></ul><!-- end field 08b03d2c-9897-4951-a437-601c66408cca --><!-- end item d2468490-5baf-4c04-8d75-837e100be70f -->","subChapters":[{"id":"41c4b786-e504-5caf-9a7a-b49917cafbea","slug":"basis-for-recommendation-666","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field dc298810-cc7f-43dc-a3db-286330facfc2 --><h4>Basis for recommendation</h4><!-- end field dc298810-cc7f-43dc-a3db-286330facfc2 -->","summary":null,"htmlStringContent":"<!-- begin item 666c8e56-4132-4aac-becf-10bed8456ecc --><!-- begin field fc3bbd08-e820-4463-a49d-f4177067abfd --><p>These recommendations are based on the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) <em>BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>], shared care guidelines for disease modifying antirheumatic drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">Gough, 2014</a>], the Royal College of Nursing (RCN) guidance <em>Assessing, managing and monitoring biologic therapies for inflammatory arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">RCN, 2015</a>], and what CKS considers good clinical practice.</p><h5>Vaccinations</h5><ul><li>Pneumococcal vaccine should be ideally given 2–4 weeks before starting a DMARD as the immunological response after starting a DMARD is thought to be reduced [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">Gough, 2014</a>].</li></ul><!-- end field fc3bbd08-e820-4463-a49d-f4177067abfd --><!-- end item 666c8e56-4132-4aac-becf-10bed8456ecc -->","subChapters":[]}]},{"id":"25b1e2c2-8ee0-58a9-bc89-df84c1a03a0a","slug":"when-to-refer","fullItemName":"When to refer","depth":3,"htmlHeader":"<!-- begin field a3f2e1bb-9c64-43bf-b739-a7f900db3c56 --><h3>When should I refer a person taking a DMARD?</h3><!-- end field a3f2e1bb-9c64-43bf-b739-a7f900db3c56 -->","summary":null,"htmlStringContent":"<!-- begin item 204b591e-b45b-4dd8-bc70-a7f900db3724 --><!-- begin field 9dd2966b-2e7a-4ed9-b3c0-a7f900db3c56 --><ul><li><strong>For people on any disease-modifying anti-rheumatic drug (DMARD), </strong><strong>consider stopping treatment and referring urgently to rheumatology if monitoring results show any of the following:</strong><ul><li>White cell count less than 3.5 x 10<sup>9</sup>/L.</li><li>Mean cell volume more than 105 fL. <ul><li>Check B12, folate, thyroid-stimulating hormone levels – if abnormal treat, if normal discuss with specialist team.</li></ul></li><li>Neutrophils less than 1.6 x 10<sup>9</sup>/L.</li><li>Creatinine has increased more than 30% over 12 months and/or calculated GFR is less than 60 mL/min.<ul><li>Repeat in 1 week, if still more than 30% from baseline, withhold and discuss with specialist team.</li></ul></li><li>Unexplained eosinophilia more than 0.5 x 10<sup>9</sup>/L.</li><li>ALT and/or AST more than 100 U/L.</li><li>Platelet count less than 140 x 10<sup>9</sup>/L.</li><li>Unexplained reduction in albumin less than 30 g/L.</li><li>Blood pressure more than 140/90mmHg. <ul><li>Manage in accordance with hypertension guidelines, unless on ciclosporin — stop treatment and discuss with specialist team. </li></ul></li><li>Urinary protein 2+ or more — check mid-stream urine sample.<ul><li>If evidence of an infection, treat appropriately. </li><li>If sterile and 2+ proteinuria or more persists on two consecutive measurements, withhold until discussed with specialist team.</li></ul></li></ul></li><li><strong>For people on any DMARD, c</strong><strong>onsider stopping treatment and referring urgently to rheumatology if the person develops any of the following signs or symptoms:</strong><ul><li>Skin/mucosal reaction — for example rash, pruritus, mouth or throat ulceration.</li><li>Sore throat.</li><li>Fever.</li><li>Unexplained bruising or bleeding.</li><li>Nausea, vomiting, diarrhoea or weight loss.</li><li>Diffuse alopecia.</li><li>Breathlessness, infection or cough.</li><li>Peripheral neuropathy.</li></ul></li><li><strong>For a person on a biologic DMARD, consider stopping treatment and referring urgently to rheumatology if the person develops any of the following: </strong><ul><li>Cough, haemoptysis, or weight loss (symptoms of tuberculosis).</li><li>Signs or symptoms of heart failure, or worsening heart failure. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li><li>Shortness of breath or dry cough (symptoms of interstitial lung disease).</li><li>Skin rashes (be aware of lupus-like syndrome).</li><li>Abdominal pain, or new abdominal symptoms.</li></ul></li></ul><!-- end field 9dd2966b-2e7a-4ed9-b3c0-a7f900db3c56 --><!-- end item 204b591e-b45b-4dd8-bc70-a7f900db3724 -->","subChapters":[{"id":"9a2e8e49-806c-5db9-926b-1e7321f9c6ab","slug":"basis-for-recommendation-f0a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b84e0fc3-ed18-43d3-a5c0-a7f900db3c64 --><h4>Basis for recommendation</h4><!-- end field b84e0fc3-ed18-43d3-a5c0-a7f900db3c64 -->","summary":null,"htmlStringContent":"<!-- begin item f0ad3a31-99f2-41d1-81de-a7f900db3c64 --><!-- begin field e8565ee8-a5bc-46a7-af9f-a7f900db3c64 --><p>These recommendations are based on the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) <em>BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>], a shared care shared care guideline for disease modifying antirheumatic drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">NHS Worcestershire, 2017</a>], the Royal College of Nursing (RCN) guidance <em>Assessing, managing and monitoring biologic therapies for inflammatory arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">RCN, 2015</a>], and  the American College of Rheumatology guideline for the treatment of rheumatoid arthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ACR, 2015</a>], and the Summary of Product Characteristics for tocilizumab [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017m</a>].</p><!-- end field e8565ee8-a5bc-46a7-af9f-a7f900db3c64 --><!-- end item f0ad3a31-99f2-41d1-81de-a7f900db3c64 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}